Jaka jest cena za National Graphite Corp. (NGRC)

Cena za National Graphite Corp. (NGRC) wynosi $0.021

Jaka jest kapitalizacja rynkowa dla National Graphite Corp. (NGRC)

Kapitalizacja rynkowa dla National Graphite Corp. (NGRC) wynosi $3.24M

Zyski National Graphite Corp. (NGRC)

National Graphite Corp. (NGRC), operating through its subsidiary Biotech Development Corp., functions as a biopharmaceutical enterprise specializing in risk and cost-sharing models. The company establishes partnerships with clinical-stage firms dedicated to developing novel biological entities or innovative therapeutic platforms. These collaborations aim to address a wide spectrum of health conditions, encompassing common illnesses, rare disorders, and those with significant unmet medical requirements. Among its key pipeline developments is ELAFIN, a drug candidate identified as a human-identical protein. ELAFIN is being developed specifically for the management of postoperative inflammatory complications. The advancement of ELAFIN is further supported by a collaboration agreement with Proteo Inc. Founded in 2006, National Graphite Corp. was formerly known as Lucky Boy Silver Corporation until it officially adopted its current name in May 2012. The company maintains its operational headquarters in Duesseldorf, Germany.

Rok	Zyski	Zmień
Za mało danych dla podanych dat.

Rok

Zyski

Zmień

Za mało danych dla podanych dat.

Firma	Zyski	Różnica w zyskach	Kraj
Clone Algo Technologies Inc. CATI.US	-	-	US
Worldwide Webb Acquisition Corp. WWAC.US	-	-	US
Gushen, Inc. GSHN.US	-	-	CN
Apollo Strategic Growth Capital APSG.US	-	-	US
Digital World Acquisition Corp. DWAC.US	-	-	US

Firma

Zyski

Różnica w zyskach

Kraj